 In Europe, there are currently no regulations requiring pharmaceutical companies to disclose their research and development, R&D, payments to healthcare professionals and institutions. Instead, these payments are typically made under a self-regulated system, whereby companies decide which activities and payments they consider to be R&D. This has led to a significant amount of money being left unaccounted for and potential conflicts of interest going unnoticed. To address this issue, we propose a unified European approach to R&D payment disclosure, including clear definitions and a centralized database. This article was authored by Pyotr Ozieransky, Lukmartinon, Pierre Lenjakiet, and others.